View Author
patient cancer tumor level breast breast cancer response factor treatment effect infusion analysis tamoxifen prognostic model lymph plasma study base model status protein therapy dataset value vegf levels growth month survival chemotherapy il -6 adjuvant table tamoxifen treatment urokinase-type plasminogen activator pro-trh mrna hormone growth factor lymph node status curve variable pro-trh result plasminogen lymph node-positive patients group angiogenesi activator thyroid node-negative <.001 breast cancer patients lymph node-negative patients receptor expression tamoxifen therapy library erasmus mc assay saline prognostic value production decreasein hormone-receptor status cancer institute interleukin concentration secretion multivariate decrease tumor levels breast cancer cells multivariate analysis adjuvant treatment prognostic factors prognosis inhibitor tissue disease il-l infusion function node-positive
4 Most Recent Publications
|
Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer.
(Article)
Dorssers, L.C.J. Grebenchtchikov, N. Brinkman, A. Look, M.P. Klijn, J.G.M. Geurts-Moespot, A. Span, P.N. Foekens, J.A. Sweep, C.G. |
2004-08-01
|
|
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
(Article)
Look, M.P. Kueng, W. Kates, R. Magdelenat, H. Martin, P.M. Beex, L.V. Windbichler, G. Janicke, F. Spyratos, F. Peyrat , J.P. Ricolleau, G. Cufer, T. Klijn, J.G.M. Brunner, N. Meijer van Gelder, M.E. Bendahl, P.O. Ulm, K. Schmitt, M. Eppenberger-Castori, S. Sweep, C.G. Fiets, W.E. Duggan, C. Blankenstein, M.A. Broet, P. Borstnar, S. Daxenbichler, G. Foekens, J.A. O'Higgins, N. Duffy, M.J. Daver, A. Manders, P. Romain, S. Quillien, V. Harbeck, N. Eppenberger, U. Putten, W.L.J. van Ferno, M. Christensen, I.J. Lisboa, B.W. Thomssen, C. |
2002-01-16
|
|
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer
(Article)
Foekens, J.A. Peters, H.A. Grebenchtchikov, N. Look, M.P. Meijer van Gelder, M.E. Geurts-Moespot, A. Kwast, Th.H. van der Sweep, C.G. Klijn, J.G.M. |
2001-01-01
|
|
Different effects of continuous infusion of interleukin-1 and interleukin-6 on the hypothalamic-hypophysial-thyroid axis
(Article)
Haasteren, G.A.C. van Meer, M.J. van der Hermus, A.R. Linkels, E. Klootwijk, W. Kaptein, E. Toor, H. van Sweep, C.G. Visser, T.J. Greef, W.J. de |
1994-01-01
|
